ADVERTISEMENTREMOVE AD

FDA To Decide on Pfizer COVID-19 Vaccine for Kids Under 5

Published
story-hero-img
i
Aa
Aa
Small
Aa
Medium
Aa
Large
ADVERTISEMENTREMOVE AD

The US Food and Drug Administration (FDA) has scheduled a virtual meeting of its advisors on 15 February 2022 to discuss the request for emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine for children aged 6 months through 4 years.

Pfizer and BioNTech have initiated a rolling submission seeking to amend the Emergency Use Authorization of its COVID-19 vaccine to include children in the age groups of 6 months to four years.

They expect to complete the EUA submission in the coming days. The application seeks authorization for the first two doses of a planned three-dose primary series of vaccinations for this age group.

ADVERTISEMENTREMOVE AD
Data on a third dose, given at least eight weeks after completion of the second dose, are expected in the coming months, and will be submitted to the FDA to support a potential expansion of this requested EUA, according to the two companies.

The FDA authorized the Pfizer-BioNTech COVID-19 vaccine for use in children 5 through 11 years of age in October 2021, and recently authorized the use of a single booster dose in individuals 12 through 15 years of age and older.

(This story was published from a syndicated feed. Only the headline and picture has been edited by FIT.)

(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)

Speaking truth to power requires allies like you.
Become a Member
Read More
×
×